Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)
Close on Nov 17, 2026Market cap $73.93MP/E –Yield –
Coherus Oncology r&d expenses
Research and development expenses are spending on new products and technology.
Coherus Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $101.21M, up 8.3% year over year. For fiscal 2025 it was $108.89M, up 18.6% from the year before. Over ten years it grew -6.5% a year on average. The highest annual figure on record is $363.11M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.89M | +18.6% |
| FY2024 | Dec 31, 2024 | $91.83M | -16.1% |
| FY2023 | Dec 31, 2023 | $109.44M | -45.1% |
| FY2022 | Dec 31, 2022 | $199.36M | -45.1% |
| FY2021 | Dec 31, 2021 | $363.11M | +154.3% |
| FY2020 | Dec 31, 2020 | $142.76M | +51.6% |
| FY2019 | Dec 31, 2019 | $94.19M | -14.6% |
| FY2018 | Dec 31, 2018 | $110.24M | -32.1% |
| FY2017 | Dec 31, 2017 | $162.39M | -36.2% |
| FY2016 | Dec 31, 2016 | $254.44M | +19.4% |
| FY2015 | Dec 31, 2015 | $213.06M | +172.4% |
| FY2014 | Dec 31, 2014 | $78.22M | +150.1% |
| FY2013 | Dec 31, 2013 | $31.28M | -10.3% |
| FY2012 | Dec 31, 2012 | $34.89M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $21.44M | -18.5% |
| Q1 FY2026 | Mar 31, 2026 | $21.54M | -11.5% |
| Q4 FY2025 | Dec 31, 2025 | $30.97M | +49.2% |
| Q3 FY2025 | Sep 30, 2025 | $27.25M | +23.6% |
| Q2 FY2025 | Jun 30, 2025 | $26.31M | +27.7% |
| Q1 FY2025 | Mar 31, 2025 | $24.36M | -14.3% |
| Q4 FY2024 | Dec 31, 2024 | $20.76M | -21.3% |
| Q3 FY2024 | Sep 30, 2024 | $22.05M | -14.0% |
| Q2 FY2024 | Jun 30, 2024 | $20.60M | -11.5% |
| Q1 FY2024 | Mar 31, 2024 | $28.42M | -16.8% |
| Q4 FY2023 | Dec 31, 2023 | $26.37M | -9.1% |
| Q3 FY2023 | Sep 30, 2023 | $25.65M | -44.0% |
| Q2 FY2023 | Jun 30, 2023 | $23.27M | -44.1% |
| Q1 FY2023 | Mar 31, 2023 | $34.15M | -58.8% |
| Q4 FY2022 | Dec 31, 2022 | $29.02M | -42.8% |
| Q3 FY2022 | Sep 30, 2022 | $45.81M | -15.3% |
| Q2 FY2022 | Jun 30, 2022 | $41.61M | -24.0% |
| Q1 FY2022 | Mar 31, 2022 | $82.92M | -59.3% |
| Q4 FY2021 | Dec 31, 2021 | $50.76M | +13.7% |
| Q3 FY2021 | Sep 30, 2021 | $54.09M | +39.2% |
| Q2 FY2021 | Jun 30, 2021 | $54.77M | +109.2% |
| Q1 FY2021 | Mar 31, 2021 | $203.49M | +514.6% |
| Q4 FY2020 | Dec 31, 2020 | $44.63M | +27.7% |
| Q3 FY2020 | Sep 30, 2020 | $38.85M | +80.1% |
| Q2 FY2020 | Jun 30, 2020 | $26.17M | +38.6% |
| Q1 FY2020 | Mar 31, 2020 | $33.11M | +76.2% |
| Q4 FY2019 | Dec 31, 2019 | $34.95M | +31.1% |
| Q3 FY2019 | Sep 30, 2019 | $21.57M | -31.8% |
| Q2 FY2019 | Jun 30, 2019 | $18.88M | -28.8% |
| Q1 FY2019 | Mar 31, 2019 | $18.79M | -26.2% |
| Q4 FY2018 | Dec 31, 2018 | $26.66M | -15.3% |
| Q3 FY2018 | Sep 30, 2018 | $31.60M | -25.9% |
| Q2 FY2018 | Jun 30, 2018 | $26.52M | -23.1% |
| Q1 FY2018 | Mar 31, 2018 | $25.46M | -52.7% |
| Q4 FY2017 | Dec 31, 2017 | $31.49M | -46.6% |
| Q3 FY2017 | Sep 30, 2017 | $42.63M | -34.0% |
| Q2 FY2017 | Jun 30, 2017 | $34.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $53.78M | – |
| Q4 FY2016 | Dec 31, 2016 | $59.01M | – |
| Q3 FY2016 | Sep 30, 2016 | $64.57M | – |
See a number that looks wrong?